Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
USP21 inhibitor
- Development stage
- Preclinical
- Lead developer
- Bayer
- Modality
- Small Molecules
01
Overview
USP21 inhibitor is an early-stage small-molecule inhibitor program being developed by Molecure targeting the deubiquitinase USP21 for the treatment of cancer, specifically focusing on cancer metabolism. USP21 is a deubiquitinating enzyme (DUB) that plays a significant role in modulating cancer cell metabolism by affecting mitochondrial function and ATP production. By inhibiting USP21, the program aims to disrupt the metabolic regulation that supports tumor cell proliferation and migration. The project is currently in the hit-to-lead stage, focusing on optimizing identified molecules for activity, selectivity, and pharmacological profile.
- Other names
- USP21 inhibitor (Molecure)USP21 small molecule inhibitorUSP-21 small molecule inhibitorUSP 21 small molecule inhibitor
02
Targets
USP10 (Ubiquitin-specific peptidase 10)USP22 (Ubiquitin-specific peptidase 22)USP21 (Ubiquitin-specific protease 21)
Beyond the preview
Go deeper on USP21 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on USP21 inhibitor.